Sudeep Pharma Limited
Sudeep Pharma Limited operates in Specialty Chemicals, part of the Chemicals sector. It booked ₹158 cr of revenue in its latest quarter (Q1 FY27) and kept 25.6% of sales as profit.
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
“Unit 4 - Nandesari Pharmaceutical excipients and next-generation higher-value molecules Set up in 2026, Unit 4 is built for the Company’s next phase of growth. It addresses two simultaneous imperatives: meeting growing volume demand for pharmaceutical excipients and infant nutrition, and enabling the commercialisation of next-generation, high-margin molecules.”
Healthier than 55% of companies in Chemicals, on the 5 of 6 measures we could read for it. Each measure is ranked against the 38–44 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 44
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in SUDEEPPHRM?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹158 cr |
| Other Income | ₹5 cr |
| Total Income | ₹164 cr |
| Cost of Materials | ₹69 cr |
| Purchases of Stock-in-Trade | ₹0 cr |
| Inventory Change (±) | ₹-12 cr |
| Employee Benefit Expense | ₹14 cr |
| Finance Costs | ₹2 cr |
| Depreciation & Amortisation | ₹4 cr |
| Other Expenses | ₹32 cr |
| Total Expenses | ₹109 cr |
| Profit before Tax | ₹54 cr |
| Tax Expense | ₹14 cr |
| Net Profit | ₹41 cr |
| Net margin on total income | 24.8% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 172 cr | 182 cr | 158 cr |
| Total income | 179 cr | 189 cr | 164 cr |
| Expenses | 117 cr | 126 cr | 109 cr |
| Profit before tax | 62 cr | 63 cr | 54 cr |
| Tax | 14 cr | 14 cr | 14 cr |
| Net profit (owners' share) | -2 cr | 49 cr | 41 cr |
| Net margin (owners' share, on revenue) | -1.2% | 26.8% | 25.6% |
| EPS (₹) | 4.29 | 4.38 | 3.59 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Pidilite Industries Limited | ₹1,552 | ₹1.58 L cr | 45.3 | 32.2% | 19.2% | — |
| Gujarat Fluorochemicals Limited | ₹4,472 | ₹49,190 cr | 55.4 | 11.2% | 13.9% | — |
| Navin Fluorine International Limited | ₹8,220 | ₹42,169 cr | 43.3 | 24.5% | 23.3% | — |
| Deepak Nitrite Limited | ₹1,605 | ₹21,889 cr | 15.9 | 23.6% | 13.4% | — |
| Aether Industries Limited | ₹1,623 | ₹21,543 cr | 85.1 | 10.2% | 19.2% | — |
| Atul Limited | ₹6,134 | ₹18,057 cr | 18.4 | 15.8% | 13.3% | — |
| Aarti Industries Limited | ₹477 | ₹17,287 cr | 27.9 | 10.4% | 6.5% | — |
| Fine Organic Industries Limited | ₹5,202 | ₹15,949 cr | 28.9 | 20.7% | 19.9% | — |
| BASF India Limited | ₹3,602 | ₹15,591 cr | 11.2 | 36.4% | 7.5% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.5 / share | 23 Jul 2026 |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 7 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.